U.S. Secretary of State Mike Pompeo says Huawei CFO Meng Wanzhou, who is under house arrest in Canada and facing extradition to America, is not a bargaining chip in the trade...Technologyread more
Boris Johnson will be meeting President Donald Trump to discuss a potential post-Brexit trade deal just as he tries to court EU leaders for a new withdrawal agreement.World Politicsread more
Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Accountants in Hong Kong took to the streets on Friday to call for the government to accept five demands of the people, including the complete withdrawal of a now-suspended...China Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Bank Indonesia on Thursday cut its key policy rate by 25 basis points to 5.5% to support growth amid an increasingly fragile global economy.Central Banksread more
Meanwhile, investors look ahead to Fed Chair Jerome Powell's speech at a yearly central banking symposium in Jackson Hole, Wyoming.Asia Marketsread more
The office has long been a breeding ground for budding romances. But actively going into business with your other half is another thing entirely.Successread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Flagging an "industry-leading" portfolio of immune-boosting cancer drugs, the company also brought forward the filing date for a new lung cancer pill and said it had the potential to win between eight and 10 new drug approvals in 2015-2016 across all disease areas.
It reiterated it was on course to return to growth and that annual sales would rise by three quarters to exceed $45 billion by 2023, a forecast it first gave in May at the height of the defense against Pfizer.
AstraZeneca executives will present further details at a six-hour investor meeting later on Tuesday. The event comes eight days before British takeover rules allow Pfizer to renew its pursuit, an option some investors now see as unlikely.
"We have more than doubled the number of potential medicines in our late-stage pipeline since 2012 and we are on track to return to growth by 2017," Chief Executive Pascal Soriot said in a statement. "Weare building a sustainable, more durable and profitable company."
Although the company has more drugs coming through, AstraZeneca still faces major challenges, with a raft of patent expiries over the next few years, and Soriot said he would continue to seek partnerships and bolt-on acquisitions to build the business.
Most investor interest is focused on the group's cancer drug portfolio, particularly in the hot area of immuno-oncology, where it has 13 combination trials underway and 16 planned.
It is also making rapid progress with a new pill against lung cancer, called AZD9291, which is now expected to be filed for U.S. approval in the second quarter of 2015. Previously, the filing date was the second-half of next year.AstraZeneca is in a race with Clovis Oncology, which is developing a similar medicine.